A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
Phase Ib Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HC010 Combinations in Patients With Advanced Solid Tumors and Determine the Recommended Dose for Subsequent Studies.
HC Biopharma Inc.
331 participants
Mar 17, 2026
INTERVENTIONAL
Conditions
Summary
Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced gastrointestinal cancer and determine the recommended dose for subsequent studies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
HC010 once every 3 weeks (Q3W) by intravenous drip
the combination chemotherapy regimens are all commonly used in clinical practice
the combination chemotherapy regimens are all commonly used in clinical practice
the combination chemotherapy regimens are all commonly used in clinical practice
HC006 once every 3 weeks (Q3W) by intravenous drip
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07477743